Subscribe - Individual

Subscribe - Biotech Premium (Corporate)


Cogstate Reports Record - Sales Up 105%

Cognitive assessment company Cogstate has signed US$73.6 million of new sales contracts, up 105% on the PCP. This is a record for the company.


In the March quarter sales contracts executed were US$19.2 million, up 44% over the PCP. Revenue trails contracts signed for the company, with revenue for the quarter US$9.3 million (up 5% on the PCP). However, several contracts were signed late in the March quarter, with normally 17% of the contract value revenue received in the quarter the contract is signed.

Operating cashflow was strong, with US$9.3 million of cash receipts and US$3 million in positive operating cashflow. Cogstate expects EBIT for the full year to be in the range of US$8.8 - US$11.3 million.

The company's backlog of clinical trial work now totals US$104 million with revenue of US$34 million already secured for FY2023. Bioshares expects profitability to continue to grow as a greater proportion of revenue will flow through to the bottom line. It also has a guaranteed US$29 million to be received from its partner Eisai for minimum sales for its cognitive tests over the next 10 years.

Cogstate is capitalised at $352 million with US$24.6 million in cash at the end of March.

Bioshares recommendation: Buy

Cogstate CEO Brad O'Connor will be speaking at next week's Bioshares Biotech Summit (11-12 May).

Information contained in this newsletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates herein expressed represent the current judgement of the publisher and are subject to change. Blake Industry and Market Analysis Pty Ltd (BIMA) and any of their associates, officers or staff may have interests in securities referred to herein (Corporations Law s.849). Details contained herein have been prepared for general circulation and do not have regard to any person’s or company’s investment objectives, financial situation and particular needs. Accordingly, no recipients should rely on any recommendation (whether express or implied) contained in this document without consulting their investment adviser (Corporations Law s.851). The persons involved in or responsible for the preparation and publication of this report believe the information herein is accurate but no warranty of accuracy is given and persons seeking to rely on information provided herein should make their own independent enquiries. Details contained herein have been issued on the basis they are only for the particular person or company to whom they have been provided by Blake Industry and Market Analysis Pty Ltd. The Directors and/or associates declare interests in the following ASX Healthcare and Biotechnology sector securities: Analyst MP: 1AD, ACR, AVR, CGS, CUV, CYC, DXB, IMM, LBT, MX1, OPT, NEU, PAB, PXS,RNO,SOM. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than $100 are not disclosed.